文献速递产科母胎医学

母胎医学会咨询系列第67号:母体脓毒症

Society for Maternal-Fetal Medicine Consult Series #67: Maternal sepsis.
PubMed 文献 · Am J Obstet Gynecol · 2023-05-24

母体脓毒症是孕产妇发病和死亡的重要原因,且为潜在可预防的死亡原因。本咨询旨在总结脓毒症已知信息,并为妊娠期和产后脓毒症管理提供指导。所引研究多来自非妊娠人群,但尽可能纳入妊娠数据。母胎医学会提出19条推荐,涵盖诊断、筛查、抗感染、液体复苏、血管活性药物、血糖管理及产后支持等。

要点

  • 对不明原因终末器官损伤的孕产妇,无论有无发热,均应考虑脓毒症诊断(GRADE 1C)。
  • 脓毒症和脓毒性休克为产科急症,须立即开始治疗和复苏(Best Practice)。
  • 疑诊脓毒症时查血乳酸(GRADE 1B);脓毒性休克或高度疑似者1小时内经验性广谱抗感染(GRADE 1C)。

核心结论

  • 母体脓毒症是孕产妇发病和死亡的重要原因,且为潜在可预防的死亡原因。
  • 本咨询总结脓毒症已知信息,并为妊娠期和产后脓毒症管理提供指导。

研究设计与样本

  • 母胎医学会(Society for Maternal-Fetal Medicine)发布的咨询系列第67号,以推荐条款形式提供指导。
  • 所引研究多来自非妊娠人群,但尽可能纳入妊娠数据。

主要发现

  • 原文未报告具体研究结果数据。

关键数值与推荐

  • 推荐对不明原因终末器官损伤且存在疑似或确诊感染的孕产妇考虑脓毒症诊断,不论有无发热(GRADE 1C)。
  • 推荐将妊娠期脓毒症和脓毒性休克视为医疗急症,立即开始治疗和复苏(Best Practice)。
  • 推荐医院和卫生系统采用脓毒症性能改进项目,包含筛查工具和指标(GRADE 1B)。
  • 推荐机构制定本机构的母体脓毒症检测程序和方案,避免单独使用单一筛查工具(GRADE 1B)。
  • 推荐对可能脓毒症的孕产妇进行感染性和非感染性病因检查以评估危及生命的器官功能障碍(Best Practice)。

临床怎么用

  • 临床对孕产妇不明原因终末器官损伤应警惕脓毒症,不因无发热而排除(GRADE 1C)。
  • 脓毒症和脓毒性休克按医疗急症立即处理,机构应建立筛查与改进项目(Best Practice、GRADE 1B)。
  • 疑诊时查血乳酸,使用平衡晶体液复苏,反对淀粉或明胶,去甲肾上腺素为一线升压药(GRADE 1B、1A、1C)。
  • 脓毒性休克1小时内经验性广谱抗感染,并快速寻找和控制感染源(GRADE 1C、Best Practice)。
  • 对脓毒性休克孕产妇使用药物性静脉血栓栓塞预防,并对幸存者及家庭提供持续全面支持(GRADE 1B、Best Practice)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Maternal sepsis is a significant cause of maternal morbidity and mortality, and is a potentially preventable cause of maternal death. This Consult aims to summarize what is known about sepsis and provide guidance for the management of sepsis during pregnancy and the postpartum period. Most studies cited are from the nonpregnant population, but where available, pregnancy data are included. The following are the Society for Maternal-Fetal Medicine recommendations: (1) we recommend that clinicians consider the diagnosis of sepsis in pregnant or postpartum patients with otherwise unexplained end-organ damage in the presence of a suspected or confirmed infectious process, regardless of the presence of fever (GRADE 1C); (2) we recommend that sepsis and septic shock in pregnancy be considered medical emergencies and that treatment and resuscitation begin immediately (Best Practice); (3) we recommend that hospitals and health systems use a performance improvement program for sepsis in pregnancy with sepsis screening tools and metrics (GRADE 1B); (4) we recommend that institutions develop their own procedures and protocols for the detection of maternal sepsis, avoiding the use of a single screening tool alone (GRADE 1B); (5) we recommend obtaining tests to evaluate for infectious and noninfectious causes of life-threatening organ dysfunction in pregnant and postpartum patients with possible sepsis (Best Practice); (6) we recommend that an evaluation for infectious causes in pregnant or postpartum patients in whom sepsis is suspected or identified includes appropriate microbiologic cultures, including blood, before starting antimicrobial therapy, as long as there are no substantial delays in timely administration of antibiotics (Best Practice); (7) we recommend obtaining a serum lactate level in pregnant or postpartum patients in whom sepsis is suspected or identified (GRADE 1B); (8) in pregnant or postpartum patients with septic shock or a high likelihood of sepsis, we recommend administration of empiric broad-spectrum antimicrobial therapy, ideally within 1 hour of recognition (GRADE 1C); (9) after a diagnosis of sepsis in pregnancy is made, we recommend rapid identification or exclusion of an anatomic source of infection and emergency source control when indicated (Best Practice); (10) we recommend early intravenous administration (within the first 3 hours) of 1 to 2 L of balanced crystalloid solutions in sepsis complicated by hypotension or suspected organ hypoperfusion (GRADE 1C); (11) we recommend the use of a balanced crystalloid solution as a first-line fluid for resuscitation in pregnant and postpartum patients with sepsis or septic shock (GRADE 1B); (12) we recommend against the use of starches or gelatin for resuscitation in pregnant and postpartum patients with sepsis or septic shock (GRADE 1A); (13) we recommend ongoing, detailed evaluation of the patient's response to fluid resuscitation guided by dynamic measures of preload (GRADE 1B); (14) we recommend the use of norepinephrine as the first-line vasopressor during pregnancy and the postpartum period with septic shock (GRADE 1C); (15) we suggest using intravenous corticosteroids in pregnant or postpartum patients with septic shock who continue to require vasopressor therapy (GRADE 2B); (16) because of an increased risk of venous thromboembolism in sepsis and septic shock, we recommend the use of pharmacologic venous thromboembolism prophylaxis in pregnant and postpartum patients in septic shock (GRADE 1B); (17) we suggest initiating insulin therapy at a glucose level >180 mg/dL in critically ill pregnant patients with sepsis (GRADE 2C); (18) if a uterine source for sepsis is suspected or confirmed, we recommend prompt delivery or evacuation of uterine contents to achieve source control, regardless of gestational age (GRADE 1C); and (19) because of an increased risk of physical, cognitive, and emotional problems in survivors of sepsis and septic shock, we recommend ongoing comprehensive support for pregnant and postpartum sepsis survivors and their families (Best Practice).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shields AD, Plante LA, Pacheco LD, et al. Society for Maternal-Fetal Medicine Consult Series #67: Maternal sepsis. Am J Obstet Gynecol. 2023. PMID: 37236495. doi:10.1016/j.ajog.2023.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。